Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma

Owen A. O'Connor, Paul A. Hamlin, Carol Portlock, Craig Moskowitz, Ariela Noy, David J. Straus, Barbara MacGregor-Cortelli, Ellen Neylon, Debra Sarasohn, Otila Dumetrescu, Diane R. Mould, Martin Fleischer, Andrew D. Zelenetz, Frank Sirotnak, Steven Horwitz

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

T-cell lymphomas (TCLs) are characterised by poor responses to therapy with brief durations of remissions. An early phase study of pralatrexate has demonstrated dramatic activity in patients with relapsed/refractory disease. Of the first 20 lymphoma patients treated, 16 had B-cell lymphoma and four had refractory aggressive TCL. All four patients with TCL achieved a complete remission. Patients with B-cell lymphoma achieved stable disease at best. For each TCL patient, the response was more durable than their best response with chemotherapy. This early experience is the first to document this unique activity of pralatrexate in TCL.

Original languageEnglish (US)
Pages (from-to)425-428
Number of pages4
JournalBritish Journal of Haematology
Volume139
Issue number3
DOIs
StatePublished - Nov 1 2007
Externally publishedYes

Fingerprint

Reduced Folate Carrier Protein
T-Cell Lymphoma
Drug Therapy
B-Cell Lymphoma
Lymphoma
10-propargyl-10-deazaaminopterin

Keywords

  • Antifolate
  • Pralatrexate
  • Reduced folate carrier
  • T-cell lymphoma

ASJC Scopus subject areas

  • Hematology

Cite this

Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma. / O'Connor, Owen A.; Hamlin, Paul A.; Portlock, Carol; Moskowitz, Craig; Noy, Ariela; Straus, David J.; MacGregor-Cortelli, Barbara; Neylon, Ellen; Sarasohn, Debra; Dumetrescu, Otila; Mould, Diane R.; Fleischer, Martin; Zelenetz, Andrew D.; Sirotnak, Frank; Horwitz, Steven.

In: British Journal of Haematology, Vol. 139, No. 3, 01.11.2007, p. 425-428.

Research output: Contribution to journalArticle

O'Connor, OA, Hamlin, PA, Portlock, C, Moskowitz, C, Noy, A, Straus, DJ, MacGregor-Cortelli, B, Neylon, E, Sarasohn, D, Dumetrescu, O, Mould, DR, Fleischer, M, Zelenetz, AD, Sirotnak, F & Horwitz, S 2007, 'Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma', British Journal of Haematology, vol. 139, no. 3, pp. 425-428. https://doi.org/10.1111/j.1365-2141.2007.06658.x
O'Connor, Owen A. ; Hamlin, Paul A. ; Portlock, Carol ; Moskowitz, Craig ; Noy, Ariela ; Straus, David J. ; MacGregor-Cortelli, Barbara ; Neylon, Ellen ; Sarasohn, Debra ; Dumetrescu, Otila ; Mould, Diane R. ; Fleischer, Martin ; Zelenetz, Andrew D. ; Sirotnak, Frank ; Horwitz, Steven. / Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma. In: British Journal of Haematology. 2007 ; Vol. 139, No. 3. pp. 425-428.
@article{f8464ed3dd8a488e8ffaf7a681e9d709,
title = "Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma",
abstract = "T-cell lymphomas (TCLs) are characterised by poor responses to therapy with brief durations of remissions. An early phase study of pralatrexate has demonstrated dramatic activity in patients with relapsed/refractory disease. Of the first 20 lymphoma patients treated, 16 had B-cell lymphoma and four had refractory aggressive TCL. All four patients with TCL achieved a complete remission. Patients with B-cell lymphoma achieved stable disease at best. For each TCL patient, the response was more durable than their best response with chemotherapy. This early experience is the first to document this unique activity of pralatrexate in TCL.",
keywords = "Antifolate, Pralatrexate, Reduced folate carrier, T-cell lymphoma",
author = "O'Connor, {Owen A.} and Hamlin, {Paul A.} and Carol Portlock and Craig Moskowitz and Ariela Noy and Straus, {David J.} and Barbara MacGregor-Cortelli and Ellen Neylon and Debra Sarasohn and Otila Dumetrescu and Mould, {Diane R.} and Martin Fleischer and Zelenetz, {Andrew D.} and Frank Sirotnak and Steven Horwitz",
year = "2007",
month = "11",
day = "1",
doi = "10.1111/j.1365-2141.2007.06658.x",
language = "English (US)",
volume = "139",
pages = "425--428",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma

AU - O'Connor, Owen A.

AU - Hamlin, Paul A.

AU - Portlock, Carol

AU - Moskowitz, Craig

AU - Noy, Ariela

AU - Straus, David J.

AU - MacGregor-Cortelli, Barbara

AU - Neylon, Ellen

AU - Sarasohn, Debra

AU - Dumetrescu, Otila

AU - Mould, Diane R.

AU - Fleischer, Martin

AU - Zelenetz, Andrew D.

AU - Sirotnak, Frank

AU - Horwitz, Steven

PY - 2007/11/1

Y1 - 2007/11/1

N2 - T-cell lymphomas (TCLs) are characterised by poor responses to therapy with brief durations of remissions. An early phase study of pralatrexate has demonstrated dramatic activity in patients with relapsed/refractory disease. Of the first 20 lymphoma patients treated, 16 had B-cell lymphoma and four had refractory aggressive TCL. All four patients with TCL achieved a complete remission. Patients with B-cell lymphoma achieved stable disease at best. For each TCL patient, the response was more durable than their best response with chemotherapy. This early experience is the first to document this unique activity of pralatrexate in TCL.

AB - T-cell lymphomas (TCLs) are characterised by poor responses to therapy with brief durations of remissions. An early phase study of pralatrexate has demonstrated dramatic activity in patients with relapsed/refractory disease. Of the first 20 lymphoma patients treated, 16 had B-cell lymphoma and four had refractory aggressive TCL. All four patients with TCL achieved a complete remission. Patients with B-cell lymphoma achieved stable disease at best. For each TCL patient, the response was more durable than their best response with chemotherapy. This early experience is the first to document this unique activity of pralatrexate in TCL.

KW - Antifolate

KW - Pralatrexate

KW - Reduced folate carrier

KW - T-cell lymphoma

UR - http://www.scopus.com/inward/record.url?scp=34848829782&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34848829782&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2007.06658.x

DO - 10.1111/j.1365-2141.2007.06658.x

M3 - Article

C2 - 17910632

AN - SCOPUS:34848829782

VL - 139

SP - 425

EP - 428

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 3

ER -